![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 04, 2023 2:18:28 PM
May 4 (Reuters) - French vaccine maker Valneva reported on Thursday a smaller-than-expected first-quarter loss as sales of travel vaccines Dukoral and Ixiaro improved, propelling its shares 16% up.
Valneva also confirmed its sales outlook for 2023, with revenue expected between 220 million euros and 260 million euros.
"We managed to double our first-quarter vaccine sales year-over-year, keeping us on track to deliver on our full-year sales guidance," Chief Financical Officer Peter Bühler said in a results statement.
After the European Commission dropped nearly all of its orders of 60 million doses of Valneva's COVID-19 vaccine last year, in a move that all but wiped out the shot's value for the company, the French drugmaker, in line with market trends, redirected its focus to the recovering travel industry.
Its Danish peer Bavarian Nordic also said in February it was to acquire a portfolio of travel vaccines from Emergent BioSolutions, as it noted a rebound in travel vaccines.
Valneva said sales for its travel vaccines Dukoral and Ixiaro more than quadrupled year-on-year, benefiting from continued recovery of travel markets and price increases.
It posted a loss of 12.3 million euros ($13.6 million), excluding interest, taxes, depreciation, and amortisation (adjusted EBITDA) in the quarter, compared with a loss of 17.8 million euros analysts forecast in a company-compiled consensus.
The drugmaker's revenue rose over 53% in the quarter to 33.5 million euros, just below analysts' expectations of 34.3 million euros, while research and development expenses fell 32% from a year earlier, driven by lower spending on the company's COVID-19 vaccine.
Valneva said regulatory filings for its Lyme disease vaccine candidate co-developed with Pfizer, are now expected in 2026, a year later than previously announced.
The two companies announced in February that they would stop testing the vaccine in roughly half of U.S. patients in a late-stage study, citing a breach of clinical trial guidelines by a third-party contractor.
($1 = 0.9022 euros) (Reporting by Greta Rosen Fondahn and Laura Lenkiewicz; Editing by Muralikumar Anantharaman and Emelia Sithole-Matarise)
Recent VALN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2024 10:05:06 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 04:16:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 04:25:32 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 04:23:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/21/2024 07:20:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2024 10:05:07 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2024 04:09:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 11:51:42 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:59:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 05:42:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 01:00:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 10:13:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 08:57:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/15/2023 06:12:25 PM
- FDA Approves Valneva's Chikungunya Virus Vaccine • Dow Jones News • 11/09/2023 11:35:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 03:40:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/07/2023 10:00:05 PM
- Thursday’s Wall Street Highlights: FedEx, Broadcom, Nio, Klaviyo, Starbucks, and more • IH Market News • 09/21/2023 11:40:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/07/2023 09:00:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/01/2023 09:00:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2023 12:00:17 PM
- Valneva Shares Slump After FDA Postpones Chikungunya Vaccine Review Date • Dow Jones News • 08/14/2023 07:55:00 AM
- Valneva Says FDA Has Delayed Chikungunya Vaccine Review Date • Dow Jones News • 08/14/2023 06:18:00 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM